Publicacions en col·laboració amb investigadors/es de Imperial College London (8)

2023

  1. Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma (Frontiers in Pharmacology, (2023), 14, (1124214), 10.3389/fphar.2023.1124214)

    Frontiers in Pharmacology

  2. Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

    Frontiers in Pharmacology, Vol. 14

2022

  1. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

  2. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 9

2020

  1. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach

    Hepatology, Vol. 72, Núm. 1, pp. 198-212

2012

  1. Radioembolization in the treatment of unresectable liver tumors: Experience across a range of primary cancers

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 35, Núm. 2, pp. 167-177

2011

  1. Research reporting standards for radioembolization of hepatic malignancies

    Journal of Vascular and Interventional Radiology, Vol. 22, Núm. 3, pp. 265-278